Peptide Therapeutics Market to surpass US$ 45.0 billion by 2026: CMI

Peptide Therapeutics Market
INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND
OPPORTUNITY ANALYSIS, 2018–2026
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Global Peptide Therapeutics Market – Global Industry Insights
The Global Peptide Therapeutics Market, by Type (Branded Peptide and Generic Peptide), by
Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease,
Infectious Disease, and Others), By Route of Administration (Oral Administration, Parenteral
Administration, and Others), was valued US$ 22.5 billion in 2018, and is projected to exhibit
a CAGR of 9.1% over the forecast period (2018 - 2026) as highlighted in a new report
published by Coherent Market Insights.
Request Sample: https://www.coherentmarketinsights.com/insight/request-sample/1837
Peptide therapeutics have wide range of applications in medicine and biotechnology and
therapeutic peptide research field. Peptide therapeutics are majorly used in the cancer
treatment and type 2 diabetes mellitus (T2DM) treatment. According to the Drug Discovery
Today, January 2015 data findings, novel peptide drug class: glucagon-like peptide-1 (GLP-1)
agonists; indicated for the treatment of type 2 diabetes mellitus (T2DM), shows lucrative
market growth, as Victoza from Novo Nordisk, is the most prominent member of the class,
reaching blockbuster status. Moreover, main area currently driving the growth of peptide
therapeutics drugs adoption are metabolic diseases and cancer treatment. Furthermore,
peptide therapeutics are in clinical testing for infectious diseases and inflammation.
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Key players in the peptide therapeutic market are engaged in expanding market share
through new product launches and regulatory approval. For instance, in March 2016, Eli Lilly
and Company introduced anti-diabetes drug Trulicity (dulaglutide) in India. Trulicity
(dulaglutide) is once-a- week non-insulin injectable belonging to class of drugs called
glucagon-like peptide (GLP-1) receptor agonist, which helps the body to release its own
insulin after the intake of food. In July 2016, U.S. Food and Drug Administration (FDA),
approved Sanofi-Aventis’s Adlyxin (lixisenatide), a once-daily injection to improve glycemic
control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.
To know the latest trends and insights related to peptide therapeutics market, click the link
below:
https://www.coherentmarketinsights.com/market-insight/peptide-therapeutics-market-1837
Peptide therapeutics market is projected to witness lucrative growth over the forecast
period, owing to the various in-organic growth strategies implemented by key manufacturing
players in this market. For instance, in July 2012, Amgen Inc. completed the acquisition of
KAI Pharmaceuticals, Inc. for a deal value of US$ 315 million. During the acquisition, KAI
Pharmaceuticals had a peptide product in development stage: KAI-4169, which is indicated
for the treatment of Secondary Hyperparathyroidism (SHPT) in patients with Chronic Kidney
Disease (CKD) who are on dialysis and is in currently in phase 2 trials. Moreover, this
acquisition allowed Amgen to acquire worldwide rights of KAI-4169, excluding Japan.
Request Customization:
https://www.coherentmarketinsights.com/insight/request-customization/1837
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Key takeaways of the Peptide Therapeutics Market:
• The global peptide therapeutics market is expected to expand at a CAGR of 9.1% during the forecast
period (2018 – 2026), owing to increasing technological advancement in peptide therapeutics by
various key players.
• Among type segment, branded therapeutic peptide is expected to witness significant growth in
peptide therapeutics market, owing to increasing investment by various key manufacturers in
research and development (R&D) for the development of branded or innovative peptide drugs and
high prescription rate.
• Cancer holds major market share in application segment due to increasing prevalence and incidence
among global population. In addition, increasing adoption of peptide therapeutics in cancer
treatment, growing awareness among the patients and healthcare professionals regarding adverse
effects of chemotherapy and growing need towards alternative therapeutics such as peptide-based
drugs, will further drive the cancer segment of peptide therapeutics market.
• Parenteral administration holds largest market share in route of administration segment, owing to
easy and increased absorption of peptide drugs into the patient’s body. According to the Drug
Discovery Today, January 2015 data findings, majority (75%) of the peptide drugs are administrated
by parenteral route.
Request Discount:
https://www.coherentmarketinsights.com/insight/request-discount/1837
© Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS
ABOUT US
Coherent Market Insights is a global market intelligence and consulting organization focused on
assisting its plethora of clients achieve transformational growth by helping them make critical business
decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our
client base includes players from across all business verticals in over 150 countries worldwide. We are
uniquely positioned to help businesses around the globe deliver practical and lasting results through
various recommendations about operational improvements, technologies, emerging market trends and
new working methods. We offer both customized and syndicated market research reports that help our
clients create visionary growth plans to provide traction to their business. We meticulously study
emerging trends across various industries at both the global and regional levels to identify new
opportunities for our clientele.
SERVICES
INDUSTRY ANALYSIS
CUSTOMIZED
RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE
SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC
STUDIES
© Coherent market Insights. All Rights Reserved
ABOUT CMI
SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
 Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry
 Component Providers and System Integrators
 Private and Government organization
 Distributors, Retailors and Value Added Resellers
 Outsourcing Companies
 Healthcare IT Solutions Developers
 Universities and Business Schools.
© Coherent market Insights. All Rights Reserved
KEY STATS
RESEARCH SOLUTIONS
100+
FEASIBILITY
STUDIES
Insights Published
Per Year
GLOBAL
REPORTS
150+
Consulting Projects
Till Date
COUNTRY
ANALYSIS
CONSULT
PROJECTS
125+
Clients Worldwide
Per Year
110+
SURVEY
RESEARCH
EXCEL
FORECAST
DATABASE
CUSTOMIZED
SOLUTIONS
COMPETITIVE
ASSESSMENT
TECHNOLOGY
SNIPPETS
Analysts and Contract
Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals,
including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in
order to result in the best possible market research reports across various industries worldwide. Based on our unmatched
expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better
outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure
sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of
opportunities posed therein.
© Coherent market Insights. All Rights Reserved
THANK YOU
To know more about us, visit our website:
www.coherentmarketinsights.com
For sales queries or new topics email us on:
[email protected]
For other queries contact:
Mr. Shah
(Manager - Business Development)
Coherent Market Insights
[email protected]
+1-206-701-6702
© Coherent market Insights. All Rights Reserved

The Global Peptide Therapeutics Market, by Type (Branded Peptide and Generic Peptide), by Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, and Others), By Route of Administration (Oral Administration, Parenteral Administration, and Others), was valued US$ 22.5 billion in 2018, and is projected to exhibit a CAGR of 9.1% over the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.